Exchange Traded Concepts LLC Trims Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Exchange Traded Concepts LLC cut its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 57.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,583 shares of the company’s stock after selling 8,897 shares during the period. Exchange Traded Concepts LLC’s holdings in Nurix Therapeutics were worth $148,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. GAMMA Investing LLC boosted its holdings in Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after purchasing an additional 3,424 shares in the last quarter. EntryPoint Capital LLC purchased a new position in Nurix Therapeutics in the first quarter valued at about $123,000. Dark Forest Capital Management LP acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at approximately $201,000. ProShare Advisors LLC raised its holdings in Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after purchasing an additional 998 shares during the last quarter. Finally, Arizona State Retirement System acquired a new stake in Nurix Therapeutics in the second quarter valued at $295,000.

Analysts Set New Price Targets

Several research firms have recently issued reports on NRIX. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $41.00 price objective on the stock. HC Wainwright upped their price target on shares of Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Nurix Therapeutics in a report on Monday. Royal Bank of Canada lowered their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Finally, Barclays increased their target price on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $29.00.

Nurix Therapeutics Trading Up 0.2 %

NASDAQ NRIX opened at $25.52 on Wednesday. The company has a market capitalization of $1.25 billion, a PE ratio of -8.74 and a beta of 2.22. Nurix Therapeutics, Inc. has a 1-year low of $4.22 and a 1-year high of $26.43. The firm’s fifty day simple moving average is $23.89 and its 200-day simple moving average is $19.81.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The firm had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. As a group, analysts predict that Nurix Therapeutics, Inc. will post -2.95 EPS for the current year.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,490 shares of the stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the sale, the chief financial officer now directly owns 54,479 shares in the company, valued at approximately $1,126,080.93. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, insider Gwenn Hansen sold 3,408 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $70,443.36. Following the transaction, the insider now owns 45,150 shares of the company’s stock, valued at approximately $933,250.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Houte Hans Van sold 2,490 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the completion of the sale, the chief financial officer now owns 54,479 shares of the company’s stock, valued at approximately $1,126,080.93. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,105 shares of company stock worth $1,507,181 in the last 90 days. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.